Clinical outcome measures following plasma exchange for MG exacerbation.

Published

Journal Article

Our objective is to report longitudinal results of the MG-ADL, MG-Composite, MG-MMT, and MG-QoL15 in an open-label trial of therapeutic plasma exchange in myasthenia gravis. Ten MG patients experiencing exacerbation had assessments prior to, immediately following, and at selected time points post-TPE. Changes from baseline to 2 weeks post-TPE were: MG-ADL median -5.0, P < 0.0033, MG-QoL15 median -13.0, P < 0.001, MG-MMT median -10.0, P < 0.0001, and MG-Composite median -10.0, P < 0.005. TPE produced a rapid, clinically significant change in all instruments, indicating these outcome measures are robust endpoints for clinical trials of rapidly efficacious MG therapies.

Full Text

Duke Authors

Cited Authors

  • Raja, SM; Howard, JF; Juel, VC; Massey, JM; Chopra, M; Guptill, JT

Published Date

  • October 2019

Published In

Volume / Issue

  • 6 / 10

Start / End Page

  • 2114 - 2119

PubMed ID

  • 31560178

Pubmed Central ID

  • 31560178

Electronic International Standard Serial Number (EISSN)

  • 2328-9503

Digital Object Identifier (DOI)

  • 10.1002/acn3.50901

Language

  • eng

Conference Location

  • United States